| Dennis Patrick Erdman, MD | |
|
6913 N Main St, Granger, IN 46530-8039 | |
| (574) 647-1500 | |
| (574) 243-4306 |
| Full Name | Dennis Patrick Erdman |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 27 Years |
| Location | 6913 N Main St, Granger, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710064241 | NPI | - | NPPES |
| 200346940 | Medicaid | IN | |
| 1710064241 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 01054224A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Hospital Of South Bend | South bend, IN | Hospital |
| Community Hospital Of Bremen Inc | Bremen, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| South Bend Emergency Physicians Inc | 0941282354 | 44 |
| Beacon Medical Group Inc | 1254243306 | 452 |
News Archive
The END7 campaign, a global advocacy campaign run by the Global Network for Neglected Tropical Diseases (NTDs) "to raise awareness of the seven most common NTDs and cultivate the resources necessary to end them by 2020," is launching a tweet chat series on Twitter, which aims to bring global health non-governmental organizations together "to ask questions and share tips on social media," a post in the Global Network's "End the Neglect" blog reports.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe psoriasis, the highest proportion of surveyed dermatologists and managed care organizations' (MCOs) pharmacy directors indicate that Abbott/Eisai's Humira and Amgen/Pfizer/Stiefel/Takeda's Enbrel have the best overall clinical profile when compared to other currently available agents.
Upsher-Smith Laboratories, Inc. today announced the successful completion of its global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology.
Four members of the United States Senate introduced legislation today to allow patients with rare diseases to participate in clinical drug studies without losing their eligibility for public healthcare coverage, echoing a move by the House of Representatives last month.
Researchers report they can generate human motor neurons from stem cells much more quickly and efficiently than previous methods allowed. The finding, described in Nature Communications, will aid efforts to model human motor neuron development, and to understand and treat spinal cord injuries and motor neuron diseases such as amyotrophic lateral sclerosis (ALS).
› Verified 4 days ago
| Entity Name | Beacon Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033161617 PECOS PAC ID: 1254243306 Enrollment ID: O20031105000657 |
News Archive
The END7 campaign, a global advocacy campaign run by the Global Network for Neglected Tropical Diseases (NTDs) "to raise awareness of the seven most common NTDs and cultivate the resources necessary to end them by 2020," is launching a tweet chat series on Twitter, which aims to bring global health non-governmental organizations together "to ask questions and share tips on social media," a post in the Global Network's "End the Neglect" blog reports.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe psoriasis, the highest proportion of surveyed dermatologists and managed care organizations' (MCOs) pharmacy directors indicate that Abbott/Eisai's Humira and Amgen/Pfizer/Stiefel/Takeda's Enbrel have the best overall clinical profile when compared to other currently available agents.
Upsher-Smith Laboratories, Inc. today announced the successful completion of its global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology.
Four members of the United States Senate introduced legislation today to allow patients with rare diseases to participate in clinical drug studies without losing their eligibility for public healthcare coverage, echoing a move by the House of Representatives last month.
Researchers report they can generate human motor neurons from stem cells much more quickly and efficiently than previous methods allowed. The finding, described in Nature Communications, will aid efforts to model human motor neuron development, and to understand and treat spinal cord injuries and motor neuron diseases such as amyotrophic lateral sclerosis (ALS).
› Verified 4 days ago
| Entity Name | South Bend Emergency Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487132114 PECOS PAC ID: 0941282354 Enrollment ID: O20181212000947 |
News Archive
The END7 campaign, a global advocacy campaign run by the Global Network for Neglected Tropical Diseases (NTDs) "to raise awareness of the seven most common NTDs and cultivate the resources necessary to end them by 2020," is launching a tweet chat series on Twitter, which aims to bring global health non-governmental organizations together "to ask questions and share tips on social media," a post in the Global Network's "End the Neglect" blog reports.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe psoriasis, the highest proportion of surveyed dermatologists and managed care organizations' (MCOs) pharmacy directors indicate that Abbott/Eisai's Humira and Amgen/Pfizer/Stiefel/Takeda's Enbrel have the best overall clinical profile when compared to other currently available agents.
Upsher-Smith Laboratories, Inc. today announced the successful completion of its global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology.
Four members of the United States Senate introduced legislation today to allow patients with rare diseases to participate in clinical drug studies without losing their eligibility for public healthcare coverage, echoing a move by the House of Representatives last month.
Researchers report they can generate human motor neurons from stem cells much more quickly and efficiently than previous methods allowed. The finding, described in Nature Communications, will aid efforts to model human motor neuron development, and to understand and treat spinal cord injuries and motor neuron diseases such as amyotrophic lateral sclerosis (ALS).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dennis Patrick Erdman, MD 3245 Health Dr, Ste 100, Granger, IN 46530-1380 Ph: (574) 647-1840 | Dennis Patrick Erdman, MD 6913 N Main St, Granger, IN 46530-8039 Ph: (574) 647-1500 |
News Archive
The END7 campaign, a global advocacy campaign run by the Global Network for Neglected Tropical Diseases (NTDs) "to raise awareness of the seven most common NTDs and cultivate the resources necessary to end them by 2020," is launching a tweet chat series on Twitter, which aims to bring global health non-governmental organizations together "to ask questions and share tips on social media," a post in the Global Network's "End the Neglect" blog reports.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe psoriasis, the highest proportion of surveyed dermatologists and managed care organizations' (MCOs) pharmacy directors indicate that Abbott/Eisai's Humira and Amgen/Pfizer/Stiefel/Takeda's Enbrel have the best overall clinical profile when compared to other currently available agents.
Upsher-Smith Laboratories, Inc. today announced the successful completion of its global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology.
Four members of the United States Senate introduced legislation today to allow patients with rare diseases to participate in clinical drug studies without losing their eligibility for public healthcare coverage, echoing a move by the House of Representatives last month.
Researchers report they can generate human motor neurons from stem cells much more quickly and efficiently than previous methods allowed. The finding, described in Nature Communications, will aid efforts to model human motor neuron development, and to understand and treat spinal cord injuries and motor neuron diseases such as amyotrophic lateral sclerosis (ALS).
› Verified 4 days ago
Patrick E Southe, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 6913 N Main St, Granger, IN 46530 Phone: 574-647-1550 Fax: 574-243-4306 | |
Wade Wenger, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 6913 N Main St, Granger, IN 46530 Phone: 574-647-1550 |